Natalizumab in Secondary Progressive Multiple Sclerosis

• Research type

  Research Study

• Full title

  A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis

• IRAS ID

  75448

• Contact name

  Raju Kapoor

• Contact email

  raj.kapoor@uclh.nhs.uk

• Sponsor organisation

  Biogen Idec Limited

• Eudract number

  201 0-021978-11

• ISRCTN Number

  ISRCTN

• REC name

  London - Central Research Ethics Committee

• REC reference

  11/LO/0537

• Date of REC Opinion

  26 Jul 2011

• REC opinion

  Further Information Favourable Opinion